IN THE CLAIMS:

Claims 1-3. (canceled)

Claim 4. (Original) A method for stimulating dengue virus specific immune response, which comprises administering to an individual an immunologically sufficient amount of two or more ~~than one~~ attenuated [[virus]] viruses chosen from the group consisting of dengue-1, dengue-2, dengue-3, and dengue-4, in a physiologically acceptable carrier.

Claim 5. (Original) The method of claim 4, wherein the attenuated virus is administered parenterally.

Claim 6. (Original) The method of claim 4, wherein the attenuated virus is administered intranasally.

Claims 7-16. (Canceled)

Claim 17. (New) The method of claim 4, which comprises administering to an individual an immunologically sufficient amount of two or more attenuated viruses chosen from the group consisting of a dengue-1 (DEN-1) virus having the sequence of DEN-1 strain 45AZ5 PDK-27 having the ATCC accession number PTA-4810, a dengue-2 (DEN-2) virus having the sequence of DEN-2 strain S16803 PDK-50 having the ATCC accession number VR-2653, a dengue-3 (DEN-3) virus having the sequence of DEN-3 strain CH53489 PDK-20 having the ATCC accession number VR-2647, and a dengue-4 (DEN-4) virus having the sequence of DEN-4 strain 341750 PDK-6 having the ATCC accession number PTA-4811, and a physiologically acceptable vehicle.

Claim 18. (New) The method of claim 4, which comprises administering to an individual an immunologically sufficient amount of a dengue-1 (DEN-1) virus having the sequence of DEN-1 strain 45AZ5 PDK-27 having the ATCC accession number PTA-4810, a dengue-2 (DEN-2) virus having the sequence of DEN-2 strain S16803 PDK-50

having the ATCC accession number VR-2653, a dengue-3 (DEN-3) virus having the sequence of DEN-3 strain CH53489 PDK-20 having the ATCC accession number VR-2647, and a dengue-4 (DEN-4) virus having the sequence of DEN-4 strain 341750 PDK-6 having the ATCC accession number PTA-4811, and a physiologically acceptable vehicle.

Claim 19. (New) The method of claim 4, which further comprises administering an adjuvant to enhance the immune response.

Claim 20. (New) The method of claim 4, wherein the attenuated viruses administered are formulated in a dose of 10^2 to 10^6 PFU/ml.

Claim 21. (New) The method of claim 4, wherein the attenuated viruses are administered subcutaneously.